Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 10, 1999, Pages 2355-2363

  Erren, Michael ^a   Reinecke, Holger ^a   Junker, Ralf ^a   Fobker, Manfred ^a   Schulte, Helmut ^a   Schurek, Josef O ^b   Kropf, Jürgen ^b   Kerber, Sebastian ^a   Breithardt, Günter ^a   Assmann, Gerd ^a   Cullen, Paul ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Acute phase response; Atherosclerosis; Coronary artery disease; Markers of inflammation; Peripheral artery disease

Indexed keywords

ACUTE PHASE PROTEIN; AMYLOID A PROTEIN; C REACTIVE PROTEIN; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; NEOPTERIN; PROCALCITONIN; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; SCORING SYSTEM;

EID: 0032849727     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.10.2355     Document Type: Article

References (71)

1. Munro JM, Cotran RS. The pathogenesis of atherosclerosis: atherogenesis and inflammation. Lab Invest. 1988;58:249-261.
2. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.
3. Alexander RW. Inflammation and coronary heart disease. N Engl J Med. 1994;331:468-469.
4. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, Maseri A. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med. 1994;331: 417-424.
5. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979.
6. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens C. Plasma concentrations of C-reactive protein and risk of developing peripheral vascular disease. Circulation. 1998;97:425-428.
7. Pepys MB. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol. 1983;34:141-212.
8. Fyfe AI, Rothenberg LS, DeBeer FC, Cantor RM, Rotter JI, Lusis AJ. Association between serum amyloid A proteins and coronary artery disease: evidence from two distinct arteriosclerotic processes. Circulation. 1997;96:2914-2919.
9. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med. 1995;332:635-641.
10. Wilhelmsen L, Svärdsudd K, Korsan-Bengsten K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med. 1984;311:501-505.
11. Assmann G, Cullen P, Heinrich J, Schulte H. Hemostatic variables in the prediction of coronary risk: results of the 8 year follow-up of healthy men in the Munster Heart Study (PROCAM). Isr J Med Sci. 1996;32:364-370.
12. Heinrich J, Schulte H, Schonfeld R, Kohler E, Assmann G. Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain. Thromb Haemost. 1995;73:374-379.
13. Bataille R, Klein B. C-reactive protein levels as a direct indicator of interleukin-6 levels in humans in vivo. Arthritis Rheum. 1992;35: 982-984.
14. van Snik J. Interleukin-6: an overview. Annu Rev Immunol. 1993;8: 253-278.
15. Rus HG, Vlaicu R, Niculescu F. Interleukin-6 and interleukin-8 protein and gene expression in human arterial atherosclerotic wall. Atherosclerosis. 1996;127:263-271.
16. Seino Y, Ikeda U, Ikeda M, Hasegawa T, Misawa Y, Yamamoto K, Kano S, Shimada K. Interleukin 6 gene transcripts are expressed in human atherosclerotic lesions. Cytokine. 1994;6:87-91.
17. Szekanecz Z, Shah MR, Pearce WH, Koch AE. Human atherosclerotic abdominal aortic aneurysms produce interleukin (IL)-6 and interferon-γ but not IL-2 and IL-4: the possible role for IL-6 and interferon-γ in vascular inflammation. Agents Actions. 1994;42:159-162.
18. Kirschenlohr HL, Metcalfe JC, Weissberg PL, Grainger DJ. Proliferation of human aortic vascular smooth-muscle cells in culture is modulated by active TGF-β. Cardiovasc Res. 1995;29:848-855.
19. Battegay EJ, Raines EW, Seifert RA, Bowen PDF, Ross R. TGF-β induces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop. Cell. 1990;63:515-524.
20. Moses HL, Yang EY, Pietenpol JA. TGF-β stimulation and inhibition of cell proliferation: new mechanistic insights. Cell. 1990;63:245-247.
21. Wiseman DM, Polverini PJ, Kamp DW, Leibovich SJ. Transforming growth factor-β (TGF-β) is chemotactic for human monocytes and induces their expression of angiogenic activity. Biochem Biophys Res Commun. 1988;157:793-800.
22. Grainger DJ, Kemp BR, Metcalfe JC, Liu AC, Lawn RM, Williams NR, Grace AA, Schofield PM, Chauhan A. The serum concentration of active transforming growth factor-β is severely depressed in advanced atherosclerosis. Nat Med. 1995;1:74-79.
23. Wang XL, Liu SX, Wilcken DL. Circulating transforming growth factor β 1 and coronary artery disease. Cardiovasc Res. 1997;34:404-410.
24. Chiu B, Viira E, Tucker W, Fong IW. Chlamydia pneumoniae, cytomegalovirus, and herpes simplex virus in atherosclerosis of the carotid artery. Circulation. 1997;96:2144-2148.
25. Huber C, Batchelor JR, Fuchs D, Hausen A, Lang A, Niederwieser D, Reibnegger G, Swetly P, Troppmeier J, Wachter H. Immune response associated production of neopterin: release from macrophages primarily under control of interferonγ. J Exp Med. 1984;160:310.
26. Denz H, Fuchs D, Hausen A, Huber H, Nachbaur D, Reibnegger G, Thaler J, Werner ER, Wachter H. Value of urinary neopterin in the differential diagnosis of bacterial and viral infections. Klin Wochenschr. 1990;68:218-222.
27. Weiss G, Willeit J, Kiechl S, Fuchs D, Jarosch E, Oberhollenzer F, Reibnegger G, Tilz GP, Gerstenbrand F, Wachter H. Increased concentrations of neopterin in carotid atherosclerosis. Atherosclerosis. 1994;106: 263-271.
28. Schumacher M, Eber B, Tatzber F, Kaufmann P, Esterbauer H, Klein W. Neopterin levels in patients with coronary artery disease. Atherosclerosis. 1992;94:87-88.
29. Tatzber F, Rabl H, Koriska K, Erhart U, Puhl H, Waeg G, Krebs A, Esterbauer H. Elevated serum neopterin levels in atherosclerosis. Atherosclerosis. 1991;89:203-208.
30. Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet. 1993;341:515-518.
31. Budde T, Fechtrup C, Bosenberg E, Vielhauer C, Enbergs A, Schulte H, Assmann G, Breithardt G. Plasma Lp(a) levels correlate with number, severity and length-extension of coronary lesions in male-patients undergoing coronary arteriography for clinically suspected coronary atherosclerosis. Arterioscler Thromb. 1994;14:1730-1736.
32. Sullivan DR, Marwick TH, Freedman SB. A new method of scoring coronary angiograms to reflect extent of coronary atherosclerosis and improve correlation with major risk factors. Am Heart J. 1990;119: 1262-1267.
33. Drexel H, Steurer J, Muntwyler J, Meienberg S, Schmid HR, Schneider E, Grochenig E, Amann FW. Predictors of the presence and extent of peripheral arterial occlusive disease. Circulation. 1996;94:199-205.
34. Kropf J, Schurek JO, Wollner A, Gressner AM. Immunological measurement of transforming growth factor-β I (TGF-β1) in blood: assay development and comparison. Clin Chem. 1997;43:1965-1974.
35. Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol. 1957;17:237-246.
36. Röschlau P, Bernt E, Gruber Z. Enzymatische Bestimmung des Gesamtcholesterins im Serum. Z Klin Chem Klin Biochem. 1974;12:403-408.
37. Burstein M, Samaille J. Sur an dosage rapide du cholesterol lié aux alpha-et aux betalipoproteins du sérum. Clin Chim Acta. 1960;5:609-614.
38. Trinder P. Determination of glucose in blood using glucose oxidase with an alternative oxygen acceptor. Ann Clin Biochem. 1964;6:24-29.
39. Town MH, Gehm S, Hammer B, Ziegenhorn J. A sensitive colorimetric method for the enzymatic determination of uric acid. J Clin Chem Clin Biochem. 1985;23:591.
40. Kannel WB, Wolf PA, Castelli WP, d'Agostino RB. Fibrinogen and risk of cardiovascular disease: the Framingham Study. JAMA. 1987;258: 1183-1186.
41. Berk BC, Weintraub WS, Alexander RW. Elevation of C-reactive protein in "active" coronary artery disease. Am J Cardiol. 1990;65:168-172.
42. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR, Haines AP, Stirling Y, Imeson JD, Thompson SG. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet. 1986;2:533-537.
43. Kannel WB, d'Agostino RB, Belanger AJ. Fibrinogen, cigarette smoking, and risk of cardiovascular disease: insights from the Framingham Study. Am Heart J. 1987;113:1006-1010.
44. Edbrooke MR, Foldi J, Cheshire JK, Li F, Faulkes DJ, Woo P. Constitutive and NF-κB-like proteins in the regulation of the serum amyloid A gene by interleukin 1. Cytokine. 1991;3:380-388.
45. Nesbitt JE, Fuller GM. Transcription and translation are required for fibrinogen mRNA degradation in hepatocytes. Biochim Biophys Acta. 1991;1089:88-94.
46. Gown AM, Tsukada T, Ross R. Human atherosclerosis, II: immunocytochemical analysis of the cellular composition of human atherosclerotic lesions. Am J Pathol. 1986;125:191-207.
47. Mitchinson MJ, Ball RY. Macrophages and atherogenesis. Lancet. 1987; 2:146-148.
48. Katsuda S, Coltrera MD, Ross R, Gown AM. Human atherosclerosis, IV: immunocytochemical analysis of cell activation and proliferation in lesions of young adults. Am J Pathol. 1993;142:1787-1793.
49. Vlaicu R, Rus HG, Niculescu F, Cristea A. Immunoglobulins and complement components in human aortic atherosclerotic intima. Atherosclerosis. 1985;55:35-50.
50. Reynolds GD, Vance RP. C-reactive protein immunohistochemical localization in normal and atherosclerotic human aortas. Arch Pathol Lab Med. 1987;111:265-269.
51. Niculescu F, Rus HG, Vlaicu R. Immunohistochemical localization of C5b, S-protein, C3d and apolipoprotein B in human arterial tissues with atherosclerosis. Atherosclerosis. 1987;65:1-11.
52. Melnick JL, Hu CZ, Burek J, Adam E, Debakey ME. Cytomegalovirus DNA in arterial walls of patients with atherosclerosis. J Med Virol. 1994;42:170-174.
53. Miettinen H, Lehto S, Saikku P, Haffner SM, Ronnemaa T, Pyorala K, Laakso M. Association of Chlamydia pneumoniae and acute coronary heart disease events in non-insulin dependent diabetic and nondiabetic subjects in Finland. Eur Heart J. 1996;17:682-688.
54. Jackson LA, Campbell LA, Kuo CC, Grayston JT. Detection of Chlamydia pneumoniae in atheroma specimens. J Infect Dis. 1996;174: 893-894.
55. File TM, Bartlett JG, Cassell GH, Gaydos CA, Grayston JT, Hammerschlag MR, Jones RB, Kahn JB, Marrie TJ, Ramirez JA, Saikku P, Schachter J, Schumacher HR, Stamm WE, Stratton CW, Yu VL. The importance of Chlamydia pneumoniae as a pathogen: the 1996 consensus conference on Chlamydia pneumoniae infections. Infect Dis Clin Pract. 1997;6:S28-S31.
56. Juvonen JJ, Tuvonen T, Laurila A, Alakarppa H, Lounatmaa K, Surcel HM, Leinonen M, Kairaluoma MI, Saikku P. Demonstration of Chlamydia pneumoniae in the walls of abdominal aortic aneurysms. J Vasc Surg. 1997;25:499-505.
57. Saikku P. Chlamydia pneumoniae and atherosclerosis: an update. Scand J Infect Dis. 1997;53-56.
58. Jackson LA, Campbell LA, Kuo CC, Rodriguez DI, Lee A, Grayston JT. Isolation of Chlamydia pneumoniae from a carotid endarterectomy specimen. J Infect Dis. 1997;176:292-295.
59. Kuo CC, Coulson AS, Campbell LA, Cappuccio AL, Lawrence RD, Wang SP, Grayston JT. Detection of Chlamydia pneumoniae in atherosclerotic plaques in the walls of arteries of lower extremities from patients undergoing bypass operation for arterial obstruction. J Vasc Surg. 1997; 26:29-31.
60. Aviram M. Interaction of oxidized low density lipoprotein with macrophages in atherosclerosis, and the antiatherogenicity of antioxidants. Eur J Clin Chem Clin Biochem. 1996;34:599-608.
61. Andalibi A, Liao F, Imes S, Fogelman AM, Lusis AJ. Oxidized lipoproteins influence gene expression by causing oxidative stress and activating the transcription factor NF-κ. Biochem Soc Trans. 1993;21: 651-655.
62. Wick G, Schett G, Amberger A, Kleindienst R, Xu QB. Is atherosclerosis an immunologically mediated disease? Immunol Today. 1995;16:27-33.
63. Shimokama T, Haraoka S, Watanabe T. Immunohistochemical and ultrastructural demonstration of the lymphocyte-macrophage interaction in human aortic intima. Mod Pathol. 1991;4:101-107.
64. Kishikawa H, Shimokama T, Watanabe T. Localization of T lymphocytes and macrophages expressing IL-1, IL-2 receptor, IL-6 and TNF in human aortic intima: role of cell-mediated immunity in human atherogenesis. Virchows Arch. 1993;423:433-442.
65. Falkensammer G, Wick G. Dendritic cells in the intima of arteries of children. J Invest Dermatol. 1997;109:15.
66. Hatanaka K, Li XA, Masuda K, Yutani C, Yamamoto A. Immunohistochemical localization of C-reactive protein-binding sites in human atherosclerotic aortic lesions by a modified streptavidin-biotin staining method. Pathol Int. 1995;45:635-641.
67. Rocken C, Kisilevsky R. Binding and endocytosis of murine high density lipoprotein from healthy (HDL) and inflamed donors (HDLSAA) by murine macrophages in vitro: a light and electron microscopic investigation. Amyloid Int J Exp Clin Invest. 1997;4:259-273.
68. Ettinger WH, Sun WH, Binkley N, Kouba E, Ershler W. Interleukin-6 causes hypocholesterolemia in middle-aged and old rhesus-monkeys. J Gerontol A Biol Sci Med Sci. 1995;50:M137-M140.
69. Grainger DJ, Mosedale DE, Metcalfe JC, Weissberg PL, Kemp PR. Active and acid-activatable TGF-β in human sera, platelets and plasma. Clin Chim Acta. 1995;235:11-31.
70. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality: 30 years of follow-up from the Framingham study. JAMA. 1987;257:2176-2180.
71. Assmann G, Cullen P, Schulte H. The Munster Heart Study (PROCAM): results of follow-up at 8 years. Eur Heart J. 1998;19:A2-A11.